查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914701

癌症切片檢查市場－全球產業規模、佔有率、趨勢、機會及預測（按產品類型、切片檢查類型、應用、最終用戶、地區和競爭格局分類），2021-2031年

Cancer Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type of Biopsy (Tissue Biopsies, Liquid Biopsies, Others), By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球癌症切片檢查市場預計將從2025年的367.3億美元成長到2031年的685.9億美元，複合年成長率（CAGR）為10.97%。癌症切片檢查是指採集體液或組織樣本進行病理分析，以確認是否有惡性腫瘤及其類型。推動市場成長的因素包括全球腫瘤疾病發生率的上升以及人們對微創診斷方法（有助於早期發現）的日益青睞。例如，美國癌症協會估計，2024年美國將新增2,001,140例癌症病例。如此巨大的疾病負擔直接導致診斷量增加，並推動了整個醫療保健系統對可靠切片檢查產品的持續需求。

市場概覽
預測期 2027-2031
市場規模：2025年 367.3億美元
市場規模：2031年 685.9億美元
複合年成長率：2026-2031年 10.97%
成長最快的細分市場 乳癌
最大的市場 亞太地區

儘管該領域發展前景廣闊，但仍面臨許多限制其潛在擴張的重大障礙。其中一個主要障礙是合格病理學家和放射科醫生短缺，而他們對於準確解讀複雜檢體至關重要。這種專業人才的短缺造成了診斷瓶頸，並限制了必要的切片檢查服務的可及性，尤其是在資源匱乏的地區。

市場促進因素

液態生物檢體技術的突破性進展正在從根本上改變這一領域，為傳統的組織取樣提供了一種微創替代方案。這項創新只需簡單的抽血即可檢測循環腫瘤DNA (ctDNA)，從而實現對疾病進展和治療反應的即時追蹤，且無需承擔手術風險。其提供全面基因組分析的能力正推動腫瘤科醫師迅速採用此技術，尤其適用於組織取樣困難或需要長期監測的患者。檢測量的顯著成長也印證了這項轉變。 Guardant Health在2025年1月發布的「2024年第四季及全年初步業績」報告中指出，臨床癌症檢測量約為206,700例，年成長20%，凸顯了臨床對這些先進診斷工具日益成長的需求。

同時，政府主導的癌症篩檢計畫擴展計畫透過在大規模人群中系統化早期檢測工作，顯著提高了癌症診斷率。公共衛生部門正在加快推行針對常見惡性腫瘤（如乳癌、大腸癌和子宮頸癌）的強制性或建議性篩檢項目，旨在透過早期療育降低死亡率。例如，英國國家醫療服務體系（NHS）英格蘭數位部門於2025年2月發布的《2023-2024年英格蘭乳癌篩檢計畫》報告顯示，該計畫篩檢了195萬名女性，成功檢測出16677例癌症，凸顯了政府支持的診斷工作規模之大。鑑於日益加重的疾病負擔，這種積極主動的方法至關重要。世界衛生組織（WHO）於2024年2月估計，2022年全球將新增2,000萬例癌症病例，凸顯了建立健全的全球篩檢和切片檢查基礎設施的迫切需求。

市場挑戰

熟練的病理學家和放射科醫生短缺是限制全球切片檢查市場擴張的一大瓶頸。這些專業人員在診斷流程中至關重要，負責指導精準的切片檢查操作並解讀複雜的組織檢體。由於人手不足，醫療機構面臨營運瓶頸，嚴重限制了其常規診斷能力。檢體處理效率低下導致大量結果積壓，檢測結果週轉時間延長。這實際上限制了可進行和計費的切片檢查數量，導致切片檢查耗材和設備的使用率低。反過來，這也阻礙了製造商的產生收入。

近期產業數據顯示，人才短缺的嚴重性已被印證：根據英國皇家放射學院預測，英國2024年，英國臨床放射學領域將出現30%的人才缺口。這一短缺迫使醫院優先處理急診病例，而非常規診斷篩檢，從而有效降低了整體切片檢查手術能力。由於缺乏執行和分析檢測的專業人才，診斷產品的需求無法得到滿足，人才短缺直接阻礙了市場成長。

市場趨勢

人工智慧 (AI) 與組織病理學的融合正在革新切片檢查樣本的解讀，顯著提升了準確性和工作流程效率。基於海量組織影像資料集訓練的演算法能夠幫助病理學家高精度地識別惡性細胞，從而降低觀察者間的差異，並消除診斷瓶頸。這項技術變革使檢查室能夠突破傳統顯微鏡的限制，處理更多樣本，並將臨床數據整合到全面的病患畫像中。 Tempus AI 於 2024 年 11 月發布的「2024 會計年度第三季財務業績報告」預測，公司營收將達到 1.809 億美元（年成長 33%），凸顯了其人工智慧驅動的精準醫療平台日益成長的商業性應用。該平台利用海量的臨床和分子數據來輔助診斷決策。

同時，用於組織採集的機器人輔助平台的引入，正在為手術精度和病人安全樹立新的標準。這些自動化系統利用先進的導航技術和關節活動能力，能夠到達傳統手動技術難以觸及的解剖位置，例如肺外周區域。透過穩定器械運動並提供即時視覺化，機器人平台顯著提高了組織樣本的診斷價值，同時最大限度地減少了對周圍健康組織的損傷。這些系統的市場吸引力顯而易見。在2025年1月發布的「2024年第四季及全年財務業績」報告中，直覺外科公司（Intuitive Surgical）報告稱，其Ion內視鏡系統的手術量同比成長了73%，這反映出複雜切片檢查手術正迅速轉向機器人輔助介入。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球癌症切片檢查市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按產品分類（設備、套件和耗材、服務）
    • 按切片檢查類型（組織切片檢查（針刺活體組織切片和手術切片檢查）、液態生物檢體、其他）
    • 依應用領域（乳癌、結腸癌、肺癌、前列腺癌、胰腺癌、卵巢癌等）
    • 依最終使用者分類（檢測機構、醫院/診所檢查室、學術機構、研究機構）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美癌症切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲癌症切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章 亞太地區癌症切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲癌症切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲癌症切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球癌症切片檢查市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • QIAGEN NV
  • Illumina, Inc.
  • Guardant Health, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Myriad Genetics, Inc.
  • Exact Sciences Corporation
  • GRAIL, LLC
  • Lucence Diagnostics Pte. Ltd.
  • ANGLE plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 7399

The Global Cancer Biopsy Market is projected to expand from USD 36.73 Billion in 2025 to USD 68.59 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 10.97%. A cancer biopsy involves extracting fluid or tissue samples for pathological analysis to confirm the presence and specific type of malignancy. This market growth is supported by the rising global prevalence of oncological conditions and a growing preference for less invasive diagnostic methods that facilitate early detection. For instance, the American Cancer Society estimates that the United States will see 2,001,140 new cancer cases in 2024. This significant disease burden directly necessitates higher diagnostic volumes, fueling a sustained demand for reliable biopsy products across healthcare systems.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 36.73 Billion
Market Size 2031USD 68.59 Billion
CAGR 2026-203110.97%
Fastest Growing SegmentBreast Cancer
Largest MarketAsia Pacific

Despite these growth prospects, the sector faces considerable obstacles that limit its potential expansion. A primary impediment is the shortage of qualified pathologists and radiologists needed to accurately interpret complex samples. This scarcity of skilled professionals creates diagnostic bottlenecks and restricts the availability of essential biopsy services, particularly in regions with limited resources.

Market Driver

Technological breakthroughs in liquid biopsy modalities are fundamentally transforming the sector by providing a minimally invasive substitute for traditional tissue extraction. This innovation enables the detection of circulating tumor DNA (ctDNA) via a simple blood draw, allowing for real-time tracking of disease progression and treatment response without the risks inherent in surgical procedures. The ability to offer comprehensive genomic profiling is driving rapid adoption among oncologists, especially for patients with difficult tissue access or those requiring longitudinal monitoring. This shift is demonstrated by substantial volume growth; Guardant Health reported in its 'Preliminary Fourth Quarter and Full Year 2024 Results' in January 2025 that it conducted approximately 206,700 oncology clinical tests, a 20% increase from the prior year, highlighting the surging clinical demand for these advanced diagnostic tools.

Simultaneously, the broadening of government-led cancer screening initiatives is significantly boosting diagnostic volumes by systematizing early detection efforts across large populations. Public health authorities are increasingly implementing mandatory or recommended screening programs for high-prevalence malignancies such as breast, colorectal, and cervical cancers to lower mortality rates through timely intervention. For example, NHS England Digital's 'Breast Screening Programme, England, 2023-24' report from February 2025 notes that the program screened 1.95 million women and successfully detected 16,677 cancers, underscoring the massive scale of state-sponsored diagnostic activities. This proactive approach is essential given the growing disease burden; the World Health Organization estimated in February 2024 that there were 20 million new cancer cases globally in 2022, reinforcing the critical need for robust screening and biopsy infrastructure worldwide.

Market Challenge

The scarcity of skilled pathologists and radiologists acts as a severe bottleneck that directly hampers the expansion of the Global Cancer Biopsy Market. These specialists are essential to the diagnostic workflow, responsible for guiding precision biopsy procedures and interpreting complex tissue samples. When the workforce is insufficient to meet the rising volume of oncological cases, healthcare facilities face operational constraints that severely limit their daily diagnostic capacity. This inability to process samples efficiently results in significant backlogs and prolonged turnaround times for results. Consequently, the volume of performable and billable biopsy procedures is effectively capped, reducing the utilization rate of biopsy consumables and devices, which in turn stalls revenue generation for manufacturers.

The gravity of this workforce gap is confirmed by recent industry data. According to the Royal College of Radiologists, the clinical radiology sector in the United Kingdom faced a 30% workforce shortfall in 2024. Such a deficit compels hospitals to prioritize emergency cases over routine diagnostic screenings, leading to a tangible reduction in the overall throughput of biopsy procedures. This scarcity directly restricts market growth, as the demand for diagnostic products cannot be fully realized without the necessary professionals to execute and analyze the tests.

Market Trends

The integration of artificial intelligence into histopathology is revolutionizing the interpretation of biopsy samples by enhancing both accuracy and workflow efficiency. Algorithms trained on extensive datasets of tissue images assist pathologists in identifying malignant cells with high precision, thereby reducing inter-observer variability and addressing diagnostic bottlenecks. This technological shift allows laboratories to process higher sample volumes and integrate clinical data for more comprehensive patient profiling, moving beyond the limits of traditional microscopy. According to Tempus AI's 'Third Quarter 2024 Financial Results' from November 2024, the company reported revenue of $180.9 million, a 33% increase year-over-year, highlighting the growing commercial adoption of AI-enabled precision medicine platforms that leverage vast libraries of clinical and molecular data to support diagnostic decision-making.

In parallel, the adoption of robotic-assisted platforms for tissue acquisition is establishing new standards for procedural precision and patient safety. These automated systems utilize advanced navigation and articulation capabilities to access lesions in anatomical locations that are difficult to reach via conventional manual techniques, such as the peripheral lung. By stabilizing instrument movement and providing real-time visualization, robotic platforms significantly increase the diagnostic yield of tissue samples while minimizing trauma to surrounding healthy tissue. The market traction for these systems is evident; Intuitive Surgical reported in its 'Fourth Quarter and Full Year 2024 Financial Results' in January 2025 that the Ion endoluminal system saw a 73% growth in procedure volume during the fourth quarter compared to the prior year, reflecting a rapid shift towards robotic interventions for complex biopsy procedures.

Key Market Players

  • QIAGEN N.V.
  • Illumina, Inc.
  • Guardant Health, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Myriad Genetics, Inc.
  • Exact Sciences Corporation
  • GRAIL, LLC
  • Lucence Diagnostics Pte. Ltd.
  • ANGLE plc

Report Scope

In this report, the Global Cancer Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biopsy Market, By Product

  • Instruments
  • Kits and Consumables
  • Services

Cancer Biopsy Market, By Type of Biopsy

  • Tissue Biopsies (Needle and Surgical Biopsies)
  • Liquid Biopsies
  • Others

Cancer Biopsy Market, By Application

  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

Cancer Biopsy Market, By End User

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic
  • Research Centers

Cancer Biopsy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biopsy Market.

Available Customizations:

Global Cancer Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Kits and Consumables, Services)
    • 5.2.2. By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others)
    • 5.2.3. By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others)
    • 5.2.4. By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic, Research Centers)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Cancer Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type of Biopsy
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cancer Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type of Biopsy
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Cancer Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type of Biopsy
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Cancer Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type of Biopsy
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Cancer Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type of Biopsy
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cancer Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type of Biopsy
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Cancer Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type of Biopsy
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Cancer Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type of Biopsy
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Cancer Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type of Biopsy
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Cancer Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type of Biopsy
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Cancer Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type of Biopsy
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cancer Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type of Biopsy
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Cancer Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type of Biopsy
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Cancer Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type of Biopsy
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Cancer Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type of Biopsy
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Cancer Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type of Biopsy
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Cancer Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type of Biopsy
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cancer Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type of Biopsy
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Cancer Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type of Biopsy
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Cancer Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type of Biopsy
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Cancer Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type of Biopsy
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type of Biopsy
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Cancer Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type of Biopsy
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Cancer Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type of Biopsy
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cancer Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. QIAGEN N.V.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Illumina, Inc.
  • 15.3. Guardant Health, Inc.
  • 15.4. Thermo Fisher Scientific, Inc.
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. Myriad Genetics, Inc.
  • 15.7. Exact Sciences Corporation
  • 15.8. GRAIL, LLC
  • 15.9. Lucence Diagnostics Pte. Ltd.
  • 15.10. ANGLE plc

16. Strategic Recommendations

17. About Us & Disclaimer